Personalized immune-chemo for advanced lung cancer without driver mutations
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized approach to combining immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that does not have specific genetic changes (driver mutations). The goal is to see if tailoring treatment based on your immune system can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage IV non-small cell lung cancer that has not been treated with systemic therapy before.
- Your cancer must test negative for certain genetic changes like EGFR, ALK, or ROS1.
- You need to be in good general health with an ECOG performance status of 0 or 1.
- You cannot have had prior immunotherapy or certain other cancer treatments.
- You must not have active or uncontrolled brain metastases, autoimmune diseases, or serious heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
Hear when a new Advanced Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.